Medifolin

Calcium folinate, the active ingredient in Medifolin, is a folate analog presented as an oral tablet for oral use. It is used to mitigate methotrexate toxicity, enhance 5‑fluorouracil efficacy, and treat folate deficiency in patients receiving chemotherapy or with low folate levels and is indicated for patients requiring folate rescue during high‑dose chemotherapy protocols.

GNH USA supplies Medifolin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Medifolin (calcium folinate) is used in therapeutic areas that involve antifolate chemotherapy and folate metabolism disorders. - Methotrexate toxicity: Provides rescue therapy to reduce toxic effects of methotrexate. - 5‑Fluorouracil‑based cancer treatment: Enhances efficacy by stabilizing intracellular folate pools. - Folate deficiency: Restores normal folate levels in patients with documented deficiency.

Adverse reactions may occur with calcium folinate therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Transient elevation of liver enzymes: mild, usually reversible. - Headache: occasional mild headache. - Rash: mild skin erythema or itching. - Diarrhea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hepatic dysfunction: marked increase in liver enzymes or jaundice. - Bone marrow suppression: pancytopenia or severe neutropenia. - Renal toxicity: acute kidney injury in susceptible individuals. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, clinicians should consider several safety measures. - Renal function monitoring: assess creatinine clearance and adjust dose if needed. - Hepatic function monitoring: check liver enzymes periodically. - Dose adjustment in renal impairment: reduce dose or increase interval for patients with reduced clearance. - Hypersensitivity awareness: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Calcium folinate may interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - High‑dose folic acid supplementation: may diminish the intended rescue effect of calcium folinate. - Trimethoprim: can exacerbate folate deficiency and reduce efficacy. - Phenytoin: may lower folate levels and counteract therapeutic benefit.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal clearance of calcium folinate. - Cytarabine: potential additive myelosuppression. - Carboplatin: possible increase in hematologic toxicity.